{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-22-000064","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.076464+00:00","generated_at":"2026-06-21T10:33:34.735910+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aspira Women's Health gets 180-day Nasdaq extension to May 2023 to cure $1 bid price deficiency","bullets":["Received Nasdaq notice granting 180-day extension until May 29, 2023, to meet minimum $1.00 bid price requirement.","Initial cure period ended Nov 28, 2022, without compliance; extension granted due to intent to effect a reverse stock split.","If not compliant by May 29, 2023, Nasdaq will delist; company may appeal to a hearing panel.","Company must achieve closing bid price of $1.00 for 10 consecutive business days to regain compliance.","Common stock listed on Nasdaq under symbol AWH."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-22-000064","json":"https://secwatch.observer/filing/0000926617-22-000064.json","markdown":"https://secwatch.observer/filing/0000926617-22-000064.md","text":"https://secwatch.observer/filing/0000926617-22-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661722000064/0000926617-22-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661722000064/awh-20221129x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:33:34.735910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bbbd0613339bb0cb7472c169b63fdcba84f11eb","claim":"Aspira Women's Health Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"November 29, 2022, Aspira Women’s Health Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) that the Company has been granted an additional 180 calendar days, or until May 29, 2023 (as the first trading day following such period), to regain compliance with the minimum closing bid price of $1.00 per share, as is required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). As the Company previously reported on that cert","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661722000064/0000926617-22-000064-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}